FDA Approves Vonvendi to Treat von Willebrand Disease

Share this content:
FDA Approves Vonvendi to Treat von Willebrand Disease
FDA Approves Vonvendi to Treat von Willebrand Disease

TUESDAY, Dec. 8, 2015 (HealthDay News) -- Vonvendi has been approved by the U.S. Food and Drug Administration to treat adults with von Willebrand disease (VWD).

Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the as-needed treatment and control of bleeding episodes in adults diagnosed with VWD.

According to the FDA, Vonvendi was evaluated in clinical studies of 69 adults with VWD, and was found to be safe and effective for the on-demand treatment and control of bleeding episodes from a variety of different sites in the body. Generalized pruritus was the most common side effect.

"Patients with heritable bleeding disorders should meet with their health care provider to discuss appropriate measures to reduce blood loss," Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research, said in a statement. "The approval of Vonvendi provides an additional therapeutic option for the treatment of bleeding episodes in patients with von Willebrand disease."

Vonvendi is produced by Baxalta, based in Westlake Village, Calif.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths